Zofran Plaintiffs File Lawsuit Claiming Drug Exposure Caused Defects In Multiple Children

January 07, 2016 – – ZofranLegal.com reports on a lawsuit filed against GlaxoSmithKline from Texas parents who allege that fetal exposure to their anti-nausea drug Zofran caused both of their daughters to be born with serious congenital defects. The lawsuit was filed in the U.S. District Court for the District of Delaware under case number 1:15-cv-00637-UNA.

Further details found within court documents state that the mother “ingested Zofran because she was deceptively led to believe that Zofran was an appropriate drug for her use while she was pregnant.” Rather than blaming her physician for prescribing her the drug as a treatment for morning sickness, she notes that it is the manufacturer’s fault, stating that both she and her doctor “relied upon the statements of GSK”.

Zofran is an anti-emetic drug which was released to market in the early 90’s after gaining approval by the U.S. Food and Drug Administration. Interestingly enough, however, Zofran was never FDA-approved to treat pregnant women, or tested for safety on this consumer group, either. The drug was specifically given approval to treat patients who were struggling from episodes of vomiting and nausea after undergoing chemotherapy, radiation, or anesthesia.

Despite this very specific approval, manufacturer GSK went on to market the drug “off-label” as a treatment for morning sickness to the medical community and the general public. Zofran quickly became one of the most commonly prescribed morning sickness treatments, though many women may have been unaware that these prescriptions were “off-label”. GSK reportedly began to receive medical reports from doctors across the U.S., indicating that their patients had given birth to children with serious congenital defects after using the drug.

In this lawsuit, after using Zofran for morning sickness, the mother gave birth to her first daughter in 2000. The daughter was diagnosed with a malformed aorta and had a heart which was just one-fifth of the size it should be. Despite being under the care of excellent pediatric cardiac specialists, the infant girl ultimately passed away from her congenital heart defects.

Just 3 years later, the mother once again gave birth to a daughter after using Zofran for morning sickness. On this occasion, the child suffered from severe vomiting and reflux issues, and remained in the hospital for an extended period of time due to her inability to ingest and retain necessary nutrients. She was additionally diagnosed with kidney and urinary tract defects.

The plaintiffs allege that they have no prior family history of any of congenital defects of any kind, and that the development of these particular defects was the direct result of fetal exposure to Zofran while still in utero.

Many parents across the country have stepped up to file similar Zofran birth defect lawsuits. These occurrences have had a dramatic and devastating impact on many families. The attorneys at Monheit Law are working to ensure that all eligible parents will be free to investigate their legal options and file Zofran lawsuits of their own. These parents and their children may be eligible for substantial compensation. For information on case eligibility, or to ask questions, please contact the dedicated Zofran team at Monheit Law for a free consultation by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60007019